BTC$62,100.00+1.74%
ETH$1,618.16+2.82%
USDT$0.9995+0.00%
BNB$587.45+1.88%
USDC$0.99970.00%
XRP$1.13+2.70%
SOL$64.74+2.69%
TRX$0.3256+1.57%
FIGR_HELOC$1.03+0.46%
HYPE$59.71-0.03%
DOGE$0.0846+4.29%
USDS$0.9997+0.01%
LEO$9.53-0.95%
RAIN$0.0133+1.60%
XLM$0.2097+7.35%
ZEC$406.98+8.03%
BTC$62,100.00+1.74%
ETH$1,618.16+2.82%
USDT$0.9995+0.00%
BNB$587.45+1.88%
USDC$0.99970.00%
XRP$1.13+2.70%
SOL$64.74+2.69%
TRX$0.3256+1.57%
FIGR_HELOC$1.03+0.46%
HYPE$59.71-0.03%
DOGE$0.0846+4.29%
USDS$0.9997+0.01%
LEO$9.53-0.95%
RAIN$0.0133+1.60%
XLM$0.2097+7.35%
ZEC$406.98+8.03%
Danaher stock fell after the company announced a $9.9B all-cash deal to buy Masimo, expanding its diagnostics and patient monitoring business.
Danaher Corporation has outperformed market expectations in Q4 2025, reporting an EPS of $2.23 and revenue of $6.84 billion, both exceeding anticipated figures.
Danaher reported Q3 revenue of $6.1 billion and EPS of $1.89, topping estimates and maintaining a positive full-year outlook.
Danaher Corporation's second quarter results for 2025 show a notable increase in revenue and net earnings, exceeding analyst expectations.
Danaher Corporation (NYSE: DHR) reported strong Q3 results with net earnings of $818 million.
Danaher Corporation reported solid financial results for the Q2 2024, with net earnings of $907 million and revenues totaling $5.7 billion.
Danaher Corporation exceeded market expectations in Q1 2024, reporting net earnings of $1.1 billion and non-GAAP diluted net earnings per common share of $1.92.
Danaher Corporation announced strong Q4 results, outperforming expectations.